Developing novel treatments for mood disorders: Accelerating discovery

被引：68

作者：

Tamminga, CA

Nemeroff, CB

Blakely, RD

Brady, L

Carter, CS

Davis, KL

Dingledine, R

Gorman, JM

Grigoriadis, DE

Henderson, DC

Innis, RB

Killen, J

Laughren, TP

McDonald, WM

Murphy, GM

Paul, SM

Rudorfer, MV

Sausville, E

Schatzberg, AF

Scolnick, EM

Suppes, T

机构：

[1] Univ Maryland, Sch Med, Dept Psychiat, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA

[2] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA

[3] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA

[4] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA

[5] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA

[6] NIMH, Neuropharmacol Program, Mol & Cellular Neurosci Res Branch, Bethesda, MD 20892 USA

[7] NIMH, Drug Discovery Program, Mol & Cellular Neurosci Res Branch, Bethesda, MD 20892 USA

[8] NIMH, Clin Therapeut Program, Mol & Cellular Neurosci Res Branch, Bethesda, MD 20892 USA

[9] NIMH, Mol Imaging Branch, Bethesda, MD 20892 USA

[10] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA

[11] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA

[12] Columbia Univ, Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY USA

[13] Neurocrine Biosci Inc, San Diego, CA USA

[14] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA

[15] Massachusetts Gen Hosp, Boston, MA 02114 USA

[16] NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA

[17] US FDA, Rockville, MD 20857 USA

[18] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA

[19] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

[20] NCI, Div Canc Treatment & Diag, Dev Therapeut Program, Rockville, MD USA

[21] Merck Res Labs, W Point, PA USA

[22] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA

来源：

BIOLOGICAL PSYCHIATRY | 2002年 / 52卷 / 06期

关键词：

depression bipolar disorder research resources; government/industry collaboration;

D O I：

10.1016/S0006-3223(02)01470-1

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

This review was generated from discussions by the Pharmacologic and Somatic Treatments Section of the National Institute of Mental Health Strategic Plan for Mood Disorders Committee on advancing novel pharmacologic and somatic treatments for mood disorders. The opening section of the article summarizes in broad strokes, current pharmacologic treatments, and new directions in the field. Thereafter the topics focus on specific research initiatives that could advance the current therapeutics for mood disorders including new basic and clinical research in vivo human imaging procedures, somatic therapeutics, and the vast new area of pharmacogenetics. New scientific and technical opportunities exist today based on advances in basic neuroscience, opportunities in clinical testing, industry interest in advancing central nervous system therapeutics, and on active consumer advocacy groups. The question of how to bring all of these positive forces together to accelerate discovery in mood disorder therapeutics is the topic of this article.

引用

页码：589 / 609

页数：21

共 86 条

[1] DIENCEPHALIC STIMULATION AND EFFECTS OF ECT IN ENDOGENOUS-DEPRESSION [J].